APA (7th ed.) Citation

Wang, Y., Guo, H., Han, R., Wu, Y., He, T., Diao, M., . . . Zhou, C. (2026). A combined strategy of EGFR-MET bispecific antibody and HER3 ADC to overcome osimertinib resistance in NSCLC. Cellular Oncology (2211-3428), 49(1), 1. https://doi.org/10.1007/s13402-025-01152-8

Chicago Style (17th ed.) Citation

Wang, Yuanyuan, et al. "A Combined Strategy of EGFR-MET Bispecific Antibody and HER3 ADC to Overcome Osimertinib Resistance in NSCLC." Cellular Oncology (2211-3428) 49, no. 1 (2026): 1. https://doi.org/10.1007/s13402-025-01152-8.

MLA (9th ed.) Citation

Wang, Yuanyuan, et al. "A Combined Strategy of EGFR-MET Bispecific Antibody and HER3 ADC to Overcome Osimertinib Resistance in NSCLC." Cellular Oncology (2211-3428), vol. 49, no. 1, 2026, p. 1, https://doi.org/10.1007/s13402-025-01152-8.